Antifibrinolytics may be cost saving among recent recipients of combined acetylsalicylic acid and clopidogrel who undergo coronary artery bypass graft surgery.
Ray
Joel G
JG
Hamielec
Cindy M
CM
D000933:Antifibrinolytic Agents / Q000191:economics* / Q000627:therapeutic use; D001241:Aspirin / Q000191:economics* / Q000627:therapeutic use; D000077144:Clopidogrel; D001026:Coronary Artery Bypass / Q000191:economics* / Q000379:methods; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000191:economics* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use
D000933:Antifibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin